Research publications

Alfred Health research outcomes are published in a wide range of peer reviewed journals. 

Search or browse research publications by year, research area, publication type or keyword.

Clear filter
Publication Details
Compassionate access anti-tumour necrosis factor-α therapy for ulcerative colitis in Australia: the benefits to patients

Costello SP, Ghaly S, Beswick L, Pudipeddi A, Agarwal A, Sechi A, O'Connor S, Connor SJ, Sparrow MP, Bampton P, Walsh AJ, Andrews JM; Australian Inflammatory Bowel Disease Association (AIBDA)

(2015), Intern Med J, 45(6), 659-66

Lipidomic profiling in inflammatory bowel disease: comparison between ulcerative colitis and Crohn's disease

Fan F, Mundra PA, Fang L, Galvin A, Moore XL, Weir JM, Wong G, White DA, Chin-Dusting J, Sparrow MP, Meikle PJ, Dart AM

(2015), Inflamm Bowel Dis, 21(7), 1511-8

Effects of concomitant immunomodulator therapy on efficacy and safety of anti-tumor necrosis factor therapy for Crohn's disease: a meta-analysis of placebo-controlled trials

Jones JL, Kaplan GG, Peyrin-Biroulet L, Baidoo L, Devlin S, Melmed GY, Tanyingoh D, Raffals L, Irving P, Kozuch P, Sparrow M, Velayos F, Bressler B, Cheifetz A, Colombel JF, Siegel CA

(2015), Clin Gastroenterol Hepatol, 13(13), 2233-40.e1-2

Radiofrequency ablation versus resection for the treatment of early stage hepatocellular carcinoma: a multicenter Australian study

Gory I, Fink M, Bell S, Gow P, Nicoll A, Knight V, Dev A, Rode A, Bailey M, Cheung W, Kemp W, Roberts SK; Melbourne Liver Group

(2015), Scand J Gastroenterol, 50(5), 567-76

Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection: a randomized trial

Pianko S, Flamm SL, Shiffman ML, Kumar S, Strasser SI, Dore GJ, McNally J, Brainard DM, Han L, Doehle B, Mogalian E, McHutchison JG, Rabinovitz M, Towner WJ, Gane EJ, Stedman CA, Reddy KR, Roberts SK

(2015), Ann Intern Med, 163(11), 809-17

The cascade of care for an Australian community-based hepatitis C treatment service

Wade AJ, Macdonald DM, Doyle JS, Gordon A, Roberts SK, Thompson AJ, Hellard ME

(2015), PLoS One, 10(11), e0142770

Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection

Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, Towner WJ, Conway B, Ruane P, Bourlière M, Asselah T, Berg T, Zeuzem S, Rosenberg W, Agarwal K, Stedman CA, Mo H, Dvory-Sobol H, Han L, Wang J, McNally J, Osinusi A, Brainard DM, McHutchison JG, Mazzotta F, Tran TT, Gordon SC, Patel K, Reau N, Mangia A, Sulkowski M; ASTRAL-2 Investigators; ASTRAL-3 Investigators

(2015), N Engl J Med, 373(27), 2608-17

ITPA genotypes predict anemia but do not affect virological response with interferon-free faldaprevir, deleobuvir, and ribavirin for HCV infection

Asselah T, Zeuzem S, Soriano V, Bronowicki JP, Lohse AW, Müllhaupt B, Schuchmann M, Bourlière M, Buti M, Roberts SK, Gane EJ, Stern JO, Voss F, Baum P, Gallivan JP, BÖcher WO, Mensa FJ

(2015), PLoS One, 10(12), e0144004

HCV-infected patients need access now to new direct-acting antiviral agents to avert liver-related deaths

Sievert W, Razavi H, Thompson A, Zekry A, Dore GJ, Roberts SK

(2015), Med J Aust, 202(9), 479

Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis

Rutgeerts P, Feagan BG, Marano CW, Padgett L, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Zhang H, Colombel JF, Reinisch W, Gibson PR, Sandborn WJ; PURSUIT-IV study group

(2015), Aliment Pharmacol Ther, 42(5), 504-14

Poor predictive value of breath hydrogen response for probiotic effects in IBS

Yao CK, Barrett JS, Philpott H, Chung AR, van Langenberg D, Garg M, Gibson PR

(2015), J Gastroenterol Hepatol, 30(12), 1731-9

Effect of intestinal resection on quality of life in Crohn's disease

Wright EK, Kamm MA, De Cruz P, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, Liew D, Prideaux L, Lawrance IC, Andrews JM, Bampton PA, Sparrow MP, Florin TH, Gibson PR, Debinski H, Gearry RB, Macrae FA, Leong RW, Kronborg I, Radford-Smith G, Selby W, Johnston MJ, Woods R, Elliott PR, Bell SJ, Brown SJ, Connell WR, Desmond PV

(2015), J Crohns Colitis, 9(6), 452-62

Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high-risk patients - a POCER study analysis

De Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, Liew D, Prideaux L, Lawrance IC, Andrews JM, Bampton PA, Jakobovits S, Florin TH, Gibson PR, Debinski H, Gearry RB, Macrae FA, Leong RW, Kronborg I, Radford-Smith G, Selby W, Johnston MJ, Woods R, Elliott PR, Bell SJ, Brown SJ, Connell WR, Desmond PV

(2015), Aliment Pharmacol Ther, 42(7), 867-79

Abnormal fibre usage in UC in remission

James SL, Christophersen CT, Bird AR, Conlon MA, Rosella O, Gibson PR, Muir JG

(2015), Gut, 64(4), 562-70

How healthy is a gluten-free diet?

Staudacher HM, Gibson PR

(2015), Br J Nutr, 114(10), 1539-41

Editorial: predicting response to a low FODMAP diet in children

Hill P, Gibson PR

(2015), Aliment Pharmacol Ther, 42(6), 775-6

Editorial: noncoeliac gluten sensitivity - the controversy rages on

Gibson PR

(2015), Aliment Pharmacol Ther, 42(10), 1234

Systematic review: new serological markers (anti-glycan, anti-GP2, anti-GM-CSF Ab) in the prediction of IBD patient outcomes. Bonneau J, Dumestre-Perard C, Rinaudo-Gaujous M, Genin C, Sparrow M, Roblin X, Paul S

Bonneau J, Dumestre-Perard C, Rinaudo-Gaujous M, Genin C, Sparrow M, Roblin X, Paul S

(2015), Autoimmun Rev, 14(3), 231-45

How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?

Ward MG, Irving PM, Sparrow MP

(2015), World J Gastroenterol, 21(40), 11331-42

Portal hypertension: pathophysiology, diagnosis and management

Bloom S, Kemp W, Lubel J

(2015), Intern Med J, 45(1), 16-26

439 440 441 442 443